> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# West Pharmaceutical Signs $950 Million Five-Year Credit Deal, Retiring Its 2019 Loan
- URL: https://www.bullished.co/west-pharmaceutical-signs-950-million-five-year-credit-deal-retiring-its-2019-loan-b681ffe6/
- Published: 2026-10-26T21:36:42.000Z
- Updated: 2026-10-28T16:35:16.000Z
- Description: The injectable-drug packaging maker repaid $130.0 million owed on the old facility and set a $200 million term loan alongside a revolver.
- Author: Matteo Parrino
- Tags: SEC Filings, WST, Industry: Healthcare

West Pharmaceutical Services, which makes containment and delivery systems for injectable drugs, replaced its 2019 bank loan on Monday with a new five-year credit agreement carrying an [initial $950,000,000 in principal](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/creditagreement-westphar.htm?ref=bullished.co), according to an [8-K](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/wst-20261026.htm?ref=bullished.co). Bank of America is administrative agent on the deal.

## Old loan repaid, new one drawn

West used part of the new borrowings to pay off the [$130.0 million](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/wst-20261026.htm?ref=bullished.co) still outstanding under its March 28, 2019 credit agreement, then terminated that agreement. The company said it incurred no early termination penalties.

The new package has a $750 million revolving credit line and a $200 million term loan advanced on Monday. Letters of credit are capped at $50 million and swing line loans (short-term borrowings) at $90 million, both carved out of the revolver. Revolving borrowings can be made in U.S. dollars, euros, yen, Singapore dollars or other approved currencies.

The company said it intends to use proceeds for working capital, capital spending and general corporate purposes, including acquisitions and share repurchases, and to repay debt.

## Pricing floats with leverage

Borrowings are unsecured. Interest margins move with the company's net leverage ratio: 1.000% to 1.500% on revolving term SOFR loans and 1.125% to 1.750% on term SOFR loans. West will also pay a commitment fee of 0.125% to 0.225% on unused revolver capacity.

The lowest tier of pricing applies until the company delivers its compliance certificate for the quarter ended March 31, 2027, according to the credit agreement.

The main financial covenant caps net debt at 3.50 times modified EBITDA, measured at each quarter end over the preceding four quarters. That limit rises to 4.00 times during material acquisition periods, subject to certain limitations. A change of control is an event of default.

## What West makes and what comes due

West sells stoppers, seals, syringe and cartridge components, vials and self-injection devices to drug and device makers. Its 10-K for 2025 shows sales outside the U.S. were 56.7% of net sales.

The term loan begins amortizing on March 31, 2028, at $1.25 million to $2.5 million per quarter, with the balance due at maturity.

The revolver's maturity can be extended at the company's request under mechanics in the agreement, while the term loan runs to the five-year mark.

Learn

- [Item 1.01: entry into a material agreement →](https://www.bullished.co/learn/8-k-items-explained/#item-101-entry-into-a-material-agreement)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — WEST PHARMACEUTICAL SERVICES INC (WST)](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/wst-20261026.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit creditagreement-westphar.htm — WEST PHARMACEUTICAL SERVICES INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/creditagreement-westphar.htm?ref=bullished.co) — SEC EDGAR